Cardioprotective Effects of a Novel Iron Chelator, Pyridoxal 2-Chlorobenzoyl Hydrazone, in the Rabbit Model of Daunorubicin-Induced Cardiotoxicity
Open Access
- 1 December 2006
- journal article
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 319 (3) , 1336-1347
Abstract
Iron chelation is the only pharmacological intervention against anthracycline cardiotoxicity whose effectiveness has been well documented both experimentally and clinically. In this study, we aimed to assess whether pyridoxal 2-chlorobenzoyl hydrazone (o-108, a strong iron chelator) can provide effective protection against daunorubicin (DAU)-induced chronic cardiotoxicity in rabbits. First, using the HL-60 leukemic cell line, it was shown that o-108 has no potential to blunt the antiproliferative efficacy of DAU. Instead, o-108 itself moderately inhibited cell proliferation. In vivo, chronic DAU treatment (3 mg/kg weekly for 10 weeks) induced mortality (33%), left ventricular (LV) dysfunction, a troponin T rise, and typical morphological LV damage. In contrast, all animals treated with 10 mg/kg o-108 before DAU survived without a significant drop in the LV ejection fraction (63.2 ± 0.5 versus 59.2 ± 1.0%, beginning versus end, not significant), and their cardiac contractility (dP/dtmax) was significantly higher than in the DAU-only group (1131 ± 125 versus 783 ± 53 kPa/s, p < 0.05), which corresponded with histologically assessed lower extent and intensity of myocardial damage. Although higher o-108 dose (25 mg/kg) was well tolerated when administered alone, in combination with DAU it led to rather paradoxical and mostly negative results regarding both cardioprotection and overall mortality. In conclusion, we show that shielding of free intracellular iron using a potent lipophilic iron chelator is able to offer a meaningful protection against chronic anthracycline cardiotoxicity. However, this approach lost its potential with the higher chelator dose, which suggests that iron might play more complex role in the pathogenesis of this disease than previously assumed.Keywords
This publication has 44 references indexed in Scilit:
- The Evolution of Iron Chelators for the Treatment of Iron Overload Disease and CancerPharmacological Reviews, 2005
- SIH—a novel lipophilic iron chelator—protects H9c2 cardiomyoblasts from oxidative stress-induced mitochondrial injury and cell deathJournal of Molecular and Cellular Cardiology, 2005
- Molecular Pharmacology of the Interaction of Anthracyclines with IronMolecular Pharmacology, 2005
- Troponin as a marker of myocardiac damage in drug-induced cardiotoxicityExpert Opinion on Drug Safety, 2005
- On Mice, Rabbits, and Human Heart FailureCirculation, 2005
- DexrazoxaneDrugs, 2005
- Carvedilol-mediated antioxidant protection against doxorubicin-induced cardiac mitochondrial toxicityToxicology and Applied Pharmacology, 2004
- Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and CardiotoxicityPharmacological Reviews, 2004
- The current and future role of dexrazoxane as a cardioprotectant in anthracycline treatment: expert panel reviewJournal of Cancer Research and Clinical Oncology, 2003
- Mobilization of iron from reticulocytesFEBS Letters, 1979